The Radiation Therapy Oncology Group (RTOG) Community Clinical Oncology Program (CCOP) is unique in that it is the only CCOP focused solely on providing radiation (RT)-related symptom amelioration trials, as well as bringing state-of-the-art RT treatment trials to the CCOP community. The RTOG CCOP conducts trials that can only be accomplished in a RT specific group, such assessment of different fractionation schedules for the palliation of painful bone metastases, the use of stereotactic radiosurgery to palliate spinal metastases, and the use of hippocampal avoidance with RT treatment planning to minimize memory loss after whole brain RT for brain metastases. To meet our unique mission we have instituted significant strategic changes including new PI leadership;a lengthy evaluation of facilitators and barriers to concept development and patient accrual over the current grant period;a revised committee structure including a new Steering/Concept Review Committee to strengthen the science, increase our portfolio, and further engage the CCOPs and improve accrual. Objectives include: 1) provision of a cancer control research program to study interventions to prevent or manage symptoms, and the study of biological measures that will assist in earlier prediction of outcomes.
This aim i s focused on 4 research themes important to patients treated with RT: Protectants for Mucositis &Epithelial Injury;Neurocognition;Palliation &QoL;and Late Effects &Survivorship. 2) Provision of access to the full complement of clinical and translational protocols available through the RTOG to CCOP members, and 3) maintenance of an infrastructure and tools for conduct and assessment of the impact of RTOG cancer control studies. The CCOP has leveraged its NCI funding to help support these objectives by developing shared resources with the RTOG including a Translational Research Program, a Feasibility Review and Clinical Trials, Education and Recruitment Working Groups. Our past work, new vision and strategic changes will advance symptom management science and provide evidence for interventions that will ultimately improve the quality of survival for patients with cancer treated with RT.

Public Health Relevance

The unique goals of the Radiation Therapy Oncology Group's (RTOG) Community Clinical Oncology Program (CCOP) are to reduce the burden of illness and death related to cancer through treatment with radiation therapy (RT), and to prevent or reduce RT treatment related side effects. The RTOG CCOP goal is to provide evidence for interventions that will ultimately improve the quality of life for cancer survivors treated with RT.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037422-25
Application #
8310259
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (J1))
Program Officer
O'Mara, Ann M
Project Start
1994-06-01
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
25
Fiscal Year
2012
Total Cost
$4,499,349
Indirect Cost
$1,351,423
Name
American College of Radiology
Department
Type
DUNS #
062485800
City
Reston
State
VA
Country
United States
Zip Code
20191
Le, Quynh-Thu; Machtay, Mitchell (2014) Acceler-dated fractionation: the end of the era of the large, "one size fits all" trial for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 89:7-9
Schefter, Tracey; Winter, Kathryn; Kwon, Janice S et al. (2014) RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys 88:101-5
Cairncross, J Gregory; Wang, Meihua; Jenkins, Robert B et al. (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783-90
Fakhry, Carole; Zhang, Qiang; Nguyen-Tan, Phuc Felix et al. (2014) Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 32:3365-73
Mirzoeva, Salida; Paunesku, Tatjana; Wanzer, M Beau et al. (2014) Single administration of p2TA (AB103), a CD28 antagonist peptide, prevents inflammatory and thrombotic reactions and protects against gastrointestinal injury in total-body irradiated mice. PLoS One 9:e101161
Xiao, Canhua; Hanlon, Alexandra; Zhang, Qiang et al. (2014) Risk factors for clinician-reported symptom clusters in patients with advanced head and neck cancer in a phase 3 randomized clinical trial: RTOG 0129. Cancer 120:848-54
Ang, K Kian; Zhang, Qiang; Rosenthal, David I et al. (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32:2940-50
Chow, Edward; van der Linden, Yvette M; Roos, Daniel et al. (2014) Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol 15:164-71
Prabhu, Roshan S; Won, Minhee; Shaw, Edward G et al. (2014) Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. J Clin Oncol 32:535-41
Komaki, Ritsuko; Paulus, Rebecca; Blumenschein Jr, George R et al. (2014) EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol 112:30-6

Showing the most recent 10 out of 216 publications